

1634

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/500,135

FILED: 09/31/2000
 TIME: 12:34:00

Input File: A:\A688931.app
 Input Seq: N:\CRF3\08012000\I500135.raw

Does Not Comp
 Corrected Diskette Name:

1. 110- APPLICANT: Estell, David
 1. 111- Inventing Firm:
 1. 112- TITLE OF INVENTION: FEEDING PROCEEDING AN ANIMAL, ESPECIALLY PIG, WITH AND
 1. 113- METHODS OF MAKING AND USING THE SAME
 1. 114- FILE REFERENCE: A-88 8/00B/DAY
 1. 115- CURRENT APPLICATION NUMBER: 09/500,135
 1. 116- CURRENT FILING DATE: 1999-09-08
 1. 117- PRIOR APPLICATION NUMBER: 09/500,087
 1. 118- PRIOR FILING DATE: 1998-01-15
 1. 119- NUMBER OF SEQ. IN SEQ. 1
 1. 120- SOFTWARE: Patent In. Ver. 2.1
 1. 210- SEQ ID NO: 1
 1. 211- LENGTH: 119
 1. 212- TYPE: DNA
 1. 213- ORGANISM: *Escherichia coli* (strain ATCC 8739)
 1. 214- FEATURE:
 1. 215- NAME/KEY: p-114
 1. 216- LOCATION: (114)..(119)
 1. 217- FEATURE:
 1. 218- NAME/KEY: CDS
 1. 219- LOCATION: (114)..(114)
 1. 220- FEATURE:
 1. 221- NAME/KEY: name
 1. 222- LOCATION: (114)..(114)
 1. 223- OTHER INFORMATION: The num at positions 114 through 114 represents a
 1. 224- which is a code for methionine.
 1. 225- FEATURE:
 1. 226- NAME/KEY: name
 1. 227- LOCATION: (114)..(114)
 1. 228- OTHER INFORMATION: The num at positions 114 through 114 represents a
 1. 229- which is a preferred embodiment, but which may also code for
 1. 230- proline.
 1. 231- FEATURE:
 1. 232- NAME/KEY: name
 1. 233- LOCATION: (114)..(114)
 1. 234- OTHER INFORMATION: The num at positions 114 through 114 represents a
 1. 235- which is a preferred embodiment, but which may also code for
 1. 236- aspartic acid.
 1. 237- FEATURE:
 1. 238- NAME/KEY: name
 1. 239- LOCATION: (114)..(114)
 1. 240- OTHER INFORMATION: The num at positions 114 through 114 represents a
 1. 241- which is a preferred embodiment, but which may also code for
 1. 242- aspartic acid.

4-5

FYI:
 C? gtg code for
 valine

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/500,135
 DATE: 05/01/2009
 TIME: 12:05:00

Input Seq: A:\A688931.app
 Output Set: N:\CRE3\08012000\I500135.raw

```

61 120< FEATURE:
62 121< NAME/KEY: unsure
63 122< LOCATION: (120)...(120)
64 123< OTHER INFORMATION: The num at positions 128 through 130 represents
65     Aaa, which in a preferred embodiment (aa) is to
66     code for alanine, but which may also code for
67     serine.
68 124< FEATURE:
69 125< NAME/KEY: unsure
70 126< LOCATION: (121)...(121)
71 127< OTHER INFORMATION: The num at positions 131 through 132 represents
72     Aaa, which in a preferred embodiment (aa) is to
73     code for serine, but which may also code for
74     alanine.
75 128< FEATURE:
76 129< NAME/KEY: unsure
77 130< LOCATION: (122)...(122)
78 131< OTHER INFORMATION: The num at positions 133 through 134 represents
79     Aaa, which in a preferred embodiment (aa) is to
80     code for alanine, but which may also code for
81     aspartic acid.
82 132< FEATURE:
83 133< NAME/KEY: unsure
84 134< LOCATION: (123)...(123)
85 135< OTHER INFORMATION: The num at positions 135 through 136 represents
86     Aaa, which in a preferred embodiment (aa) is to
87     code for aspartic acid, but which may also code
88     for alanine.
89 136< FEATURE:
90 137< NAME/KEY: unsure
91 138< LOCATION: (138)...(138)
92 139< OTHER INFORMATION: The num at positions 139 through 139 represents
93     Aaa, which in a preferred embodiment (aa) is to
94     code for threonine, but which may also code for
95     serine.
96 140< FEATURE:
97 141< NAME/KEY: unsure
98 142< LOCATION: (140)...(140)
99 143< OTHER INFORMATION: The num at positions 141 through 141 represents
100     Aaa, which in a preferred embodiment (aa) is to
101     code for serine, but which may also code for
102     threonine.
103 144< FEATURE:
104 145< NAME/KEY: unsure
105 146< LOCATION: (141)...(141)
106 147< OTHER INFORMATION: The num at positions 142 through 142 represents
107     Aaa, which in a preferred embodiment (aa) is to
108     code for alanine, but which may also code
109     for glutamine.

```

RAW SEQUENCE LISTING

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/300,135

$$L_{\text{eff}} = \frac{1}{2} \int d^3x \left(\frac{1}{2} \dot{\phi}^2 - \frac{1}{2} \nabla^2 \phi^2 - \frac{1}{2} \phi^2 \right)$$

1. ME. 1.3. 25, 100

```
Input Set = A:\A688931.app
```

Output Set: N:\CRF3\08012000\I500135.raw

1.00 - 1.00 - SEQUENCE: 1

[illegible]

RAW SEQUENCE LISTING

PATENT APPLICATION US/09/500,135

DATE: 10/12/2018

1992, 1993, 1994, 1995

```
Input Set: A:\A688931.app
```

Output Set : N:\CRF3\08012000\1500135.raw

[illegible]

see item 10 on Eni Summary
Ala Leu Ala Leu
12
JFK

RAW SEQUENCE LISTING

PATENT INFORMATION N US/09/500,135

DATE: 05/17/2009

TIME: 11:11:00

Input Seq: A:\A688931.app

Output Seq: N:\CRF3\08012000\1500135.raw

250 Tyr Val Glu His Asp His Val Ala His Ala Thr Ala Glu Ser Val Pro
 251 100 105 110
 252 Tyr Glu Val Ser Glu His Asp Ala Pro Ala Leu His Ser Glu Asp
 253 115 120
 254 Thr Gly Ser Asp Val Leu Val Ala Val Ile Asp Ser His Thr Asp Ser
 255 125 130
 256 Ser His Thr Asp Leu Lys Val Ala Gly Gly Ala Ser Ile Val Pro Ser
 257 135 140
 W--> 258 Glu Thr Xaa Xaa Phe Glu Asp Xaa Asn Ser His Gly Thr His Val Ala
 259 145 150
 260 Gly Thr Val Ala Thr Leu Asn Ser Asp Ile Gly Val Leu Gly Val Ala
 261 155 160
 W--> 262 Pro Ser Xaa Xaa Leu Tyr Ala Val Lys Val Leu Gly Xaa Xaa Gly Ser
 263 165 170
 264 Glu Glu Tyr Ser Asp Ile Thr Ser Gly Thr Glu His Ala Ile Ala Asn
 265 175 180
 266 Asn His Asp Val Ile Asn Ser Ser Ile Gly Gly Pro Ser Asp Ser Ala
 267 185 190
 268 Ala Leu Thr Ala Val Val Asp Lys Ala Val Ala Ser Gly Val Val Val
 269 195 200
 W--> 270 Val Ala Ala Ala Gly Asn Glu Gly Xaa Xaa Gly Ser Ser Ser Thr Val
 271 205 210
 272 Gly Thr Pro Gly Thr Tyr Pro Ser Val Ile Ala Val Glu Ala Thr Asp
 273 215 220
 274 Asp Thr Asp Thr Thr Ala Ser Ile Thr Ser Val Glu Thr Glu Thr Asp
 275 225 230
 276 Val His Ala Thr Thr Val Thr Thr Ala Ser Thr Leu Thr Glu Asn Thr
 277 235 240
 278 Thr Glu Ala Thr Thr Thr Thr Thr Thr Ala Ser Pro His Val Ala Gly
 279 245 250
 280 Thr Ala Ala Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr
 281 255 260
 W--> 282 Val Arg Ser Ser Leu Xaa Asn Thr Thr Thr Lys Leu Gly Asp Ser Phe
 283 265 270
 284 Tyr Thr Gly Lys Glu Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr
 285 275 280
 286 281 THF 10 N 13
 287 281 11N12H 13N
 288 282 11N12H 13N
 289 283 11N12H 13N
 290 284 11N12H 13N
 291 285 11N12H 13N
 292 286 11N12H 13N
 293 287 11N12H 13N
 294 288 11N12H 13N
 295 289 11N12H 13N
 296 290 11N12H 13N
 297 291 11N12H 13N
 298 292 11N12H 13N
 299 293 11N12H 13N
 300 294 11N12H 13N

✓ item 10
 ✓
 ✓

✓ PSI

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

VERIFICATION SUMMARY

US 2009/050,135

DATE: 07/2/2014
TIME: 11:24

File Name: A:\A688931.app

N:\CRE3\08012000\1500135.raw

[illegible]